HypermagnesemiaMANAGEMENT

ENDOCRINE AND METABOLIC PRESENTATIONS · 12 SECTIONS

⚲

441 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

Acute Porphyria Adrenal crisis Adrenal Insufficiency (Addisonian Crisis)Dehydration Diabetes Insipidus Diabetic Ketoacidosis (DKA)Euglycemic DKA (SGLT2 inhibitor)Galactosemia GLP-1 receptor agonist complications (retained gastric contents, aspiration risk)Homocystinuria Hypercalcemia Hyperkalemia Hypermagnesemia Hypernatremia Hyperosmolar Hyperglycemic State (HHS)Hypertensive emergency Hypertensive urgency Hypocalcemia Hypoglycemia Hypogonadism (Acute Presentation)Hypokalemia Hypomagnesemia Hyponatremia Hypoparathyroidism (Tetany)Insulin pump failure Maple Syrup Urine Disease (Crisis)Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCAD)Metabolic Acidosis Metabolic Alkalosis Myasthenia gravis crisis Myxedema coma Pellagra Pheochromocytoma (Crisis)Pituitary Apoplexy Pompe Disease (GSD II)Respiratory Acidosis Respiratory Alkalosis Scurvy SIADH Starvation Ketosis Tarui Disease (GSD VII)Thyroid storm Tyrosinemia Vitamin D Deficiency (Severe-Rickets)Von Gierke Disease (GSD I)

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp53

Immediate priorities

›Airway and breathing threats

›Respiratory depression or apnea

›Serum Mg approaching 2.5 mmol/l (5 mEq/L) or clinical signs of hypoventilation

›SpO2 falling, rising end-tidal CO2, shallow respiratory rate

›If apnea or impending respiratory failure, proceed to definitive airway control

›Bag-mask ventilation immediately while preparing RSI

›Succinylcholine may have prolonged effect due to Mg-induced neuromuscular blockade; rocuronium acceptable

›Oxygenation and ventilation targets

›SpO2 target 94% to 98%

›Continuous capnography for respiratory monitoring

›Circulation threats

›Hemodynamic instability from Mg-induced vasodilation and myocardial depression

›SBP < 90 mmHg

›MAP < 65 mmHg

›Bradycardia refractory to calcium

›Calcium gluconate 10%: 10 to 20 mL (1 to 2 g) IV over 5 to 10 minutes as first-line antidote

›Directly antagonizes magnesium at neuromuscular junction and myocardium

›May repeat every 5 to 10 minutes as needed

›Transcutaneous pacing for complete heart block or symptomatic bradycardia not responding to calcium

›Vasopressors for refractory hypotension

›Norepinephrine first-line

›Continue calcium antidote concurrently

Key decision points

›Stop all exogenous magnesium immediately

›Magnesium-containing IV infusions, antacids, laxatives, supplements, bowel preps

›Notify pharmacy and nursing urgently

›Severity stratification

02History/hx45

Presentation pattern

›Core symptoms

›Nausea and vomiting (early, mild elevations)

›Flushing and warmth (vasodilatory effect)

›Lethargy and somnolence

›Progressive weakness

›Dyspnea or shallow breathing (neuromuscular blockade of respiratory muscles)

›Alarm symptoms requiring immediate escalation

›Loss of deep tendon reflexes

›Respiratory depression or apnea

›Syncope or presyncope (hypotension)

›Confusion or unresponsiveness

Exogenous magnesium exposure

›Magnesium-containing products

›OTC antacids: Maalox, Mylanta, magnesium hydroxide (Milk of Magnesia)

›OTC laxatives and cathartics: magnesium citrate, Epsom salts (MgSO4), magnesium sulfate

›Oral or IV magnesium supplements

›Epsom salt bath soaks with damaged skin (absorption risk)

›Therapeutic IV magnesium

›IV magnesium sulfate for preeclampsia or eclampsia

›IV magnesium for severe asthma exacerbation

›IV magnesium for torsades de pointes

›Total parenteral nutrition with excessive magnesium content

Risk factors

›Renal impairment

›CKD stage 4 to 5 (CrCl < 30 mL/min) is the single most important risk factor

›ESRD on dialysis with missed sessions

›Acute kidney injury

03Physical Exam/exam31

Vital signs

›Hemodynamic assessment

›Hypotension from Mg-induced vasodilation and cardiac depression

›Bradycardia

›Hypothermia in severe cases

›Respiratory rate: shallow or slow breathing is an early respiratory depression sign

Neurological exam

›Deep tendon reflexes (most critical bedside test)

›Patellar reflex is the earliest clinical sign of Mg toxicity

›Absent patellar reflex signals Mg approximately 2.0 mmol/l (4 mEq/L)

›Check bilaterally and serially

›Mental status

›Lethargy progressing to obtundation then coma

›GCS trend

›Muscle tone

›Diffuse hypotonia

›Flaccid paralysis at high levels

›Pupils

›Dilated and sluggish in severe cases

Respiratory exam

›Respiratory effort assessment

›Paradoxical breathing pattern

›Accessory muscle use

›Apnea in severe toxicity

›Respiratory rate and tidal volume adequacy

Cardiovascular exam

›Cardiac assessment

›Bradycardia severity

04Differential Diagnosis/ddx28

Life-threatening mimics

›Hyperkalemia

›ICD-10: E87.5

›Similar bradycardia, hypotension, and ECG changes; check serum potassium urgently

›May coexist in renal failure patients

›Complete heart block from other cause

›ICD-10: I44.2

›Differentiate by magnesium level and medication history

›Respiratory failure from other neuromuscular cause

›Botulism (ICD-10: A05.1): descending flaccid paralysis, no elevated serum Mg

›Guillain-Barre syndrome (ICD-10: G61.0): ascending weakness, areflexia, CSF albuminocytologic dissociation

›Myasthenic crisis (ICD-10: G70.01): fatigable weakness, normal serum Mg, responds to edrophonium

Common mimics

›Hypocalcemia

›ICD-10: E83.51

›May coexist; Mg inhibits PTH secretion causing secondary hypocalcemia

›Present in up to 7 of 8 cases of significant hypermagnesemia

›Drug overdose

›Opioid toxicity (ICD-10: T40.2): respiratory depression, pinpoint pupils, responds to naloxone

›Benzodiazepine overdose (ICD-10: T42.4): CNS depression, no ECG changes

›Calcium channel blocker overdose (ICD-10: T46.1): bradycardia, hypotension, ECG changes

›Hypothyroidism or myxedema coma

›ICD-10: E03.5

›Lethargy, hyporeflexia, hypothermia; check TSH

›Sepsis or septic shock

›ICD-10: A41.9

›Hypermagnesemia can mimic septic shock; check magnesium in all septic-appearing patients with relevant exposure history

›Addisonian crisis

05Laboratory Tests/lt33

Serum magnesium

›Serum magnesium level

›Normal range: 0.7 to 1.0 mmol/l (1.7 to 2.2 mg/dL)

›Hypermagnesemia defined as serum Mg > 1.1 mmol/l

›Severity correlation by serum level

›1.1 to 2.0 mmol/l: nausea, flushing, headache, lethargy, reduced DTRs

›2.0 to 2.9 mmol/l: somnolence, absent DTRs, hypotension, bradycardia, hypocalcemia

›2.9 to 4.0 mmol/l: flaccid paralysis, respiratory depression, ECG changes

›> 4.0 mmol/l: respiratory paralysis, complete heart block, cardiac arrest

Electrolytes and renal function

›Basic metabolic panel

›Serum creatinine and BUN: renal impairment is the primary predisposing factor

›Serum potassium: hyperkalemia may coexist in renal failure

›Serum sodium: hyponatremia may alter anion gap interpretation

›Ionized calcium

›Low ionized calcium is common; present in up to 7 of 8 cases of significant hypermagnesemia

›Mg inhibits PTH secretion leading to secondary hypocalcemia

›Concomitant hypocalcemia worsens cardiac toxicity

›Serum phosphorus

›Hyperphosphatemia common in CKD; may coexist

›Anion gap

›May be low in hypermagnesemia due to magnesium as an unmeasured cation

Acid-base and respiratory assessment

›ABG or VBG

›Assess for respiratory acidosis from hypoventilation

›Hypercapnia indicates respiratory muscle compromise

›Lactate to screen for end-organ hypoperfusion

›CBC

06Diagnostic Tests/dt36

Scoring Systems

›No validated severity scoring system specific to hypermagnesemia exists

›Management is guided by serum magnesium level combined with clinical findings

›Serial patellar reflex testing is the primary clinical severity tool

›Loss of patellar reflex: action threshold for escalation

›Loss correlates with serum Mg approximately 2.0 mmol/l (4 mEq/L)

ECG

›ECG indications and interpretation

›Obtain ECG in all patients with confirmed or suspected hypermagnesemia

›AHA recommends continuous ECG monitoring for moderate-to-severe electrolyte imbalances

›Progressive ECG changes with rising Mg

›Prolonged PR interval (first-degree AV block): early finding

›Widened QRS complex: moderate toxicity

›Prolonged QT interval: moderate to severe

›Tall peaked T waves and prominent U waves

›ST segment elevation mimicking STEMI at high levels

›High-degree AV block and complete heart block: severe toxicity

›Bradycardia progressing to asystole and cardiac arrest

MRI

›MRI in hypermagnesemia

›Not routinely indicated for diagnosis or management of hypermagnesemia

›Consider MRI brain if persistent altered mental status after Mg normalization

›Differential: posterior reversible encephalopathy syndrome in eclampsia patients

›Structural lesion in patients with unexplained neurological deficits

›CT imaging indications

›CT chest: if respiratory depression raises concern for aspiration pneumonia

›CT abdomen and pelvis: if oral Mg-containing tablets suspected to be retained in the GI tract

07Disposition/dispo23

ICU admission

›ICU admission criteria

›Serum Mg > 2.5 mmol/l (approximately 6 mg/dL) regardless of symptoms

›Any hemodynamic instability: hypotension or bradycardia

›Respiratory depression or apnea requiring ventilatory support

›Altered mental status or absent deep tendon reflexes

›Requirement for emergent hemodialysis or CRRT

›Cardiac conduction abnormalities on ECG

Monitored bed admission

›Telemetry or monitored bed criteria

›Moderate elevation (Mg 1.5 to 2.5 mmol/l) with intact reflexes and stable vitals

›Concurrent hypocalcemia requiring correction

›Underlying CKD with cleared exogenous Mg source but slow expected renal clearance

Observation and discharge

›Observation criteria

›Mild asymptomatic elevation with clearly reversible and removed cause

›Normal or near-normal renal function with trending Mg level

›Discharge criteria

›Mild elevation with cause definitively removed

›Normal renal function

›Asymptomatic with intact deep tendon reflexes

›Reliable follow-up within 24 to 48 hours for repeat Mg level

Consultations

›Required consultations

›Nephrology: renal failure requiring dialysis or severe refractory hypermagnesemia

›Obstetrics: pregnant patient on magnesium sulfate infusion with toxicity signs

›Critical care: respiratory or hemodynamic instability

08Treatment/t55

Immediate antidote

›Calcium gluconate 10%

›Dose: 10 to 20 mL (1 to 2 g) IV over 5 to 10 minutes

›Directly antagonizes magnesium at the neuromuscular junction and myocardium

›Does not lower serum Mg; provides temporary stabilization while elimination is achieved

›May repeat every 5 to 10 minutes for persistent symptoms

›Maximum: guided by clinical response and ionized calcium level

›Calcium chloride alternative

›Delivers 3 times more elemental calcium per gram than calcium gluconate

›Administer via central venous access due to tissue necrosis risk with extravasation

›Dose: 1 g IV for cardiac arrest or refractory hemodynamic instability

Airway management

›Airway intervention

›Bag-mask ventilation for apnea while preparing for definitive airway

›Rapid sequence intubation if respiratory failure or airway unprotected

›Succinylcholine: use with caution; Mg potentiates depolarizing neuromuscular blockade

›Rocuronium: reduce dose by 30 to 50% as Mg enhances non-depolarizing blockade

›Sugammadex available to reverse rocuronium rapidly if needed

Enhanced elimination

›IV fluid resuscitation for renal excretion

›Normal saline 250 to 500 mL bolus IV

›Volume expansion increases GFR and promotes Mg excretion

›Reassess volume status frequently to avoid pulmonary edema

›Only effective when renal function is intact

›Furosemide for forced diuresis

›Dose: 20 to 40 mg IV

›Loop diuretic enhances renal Mg excretion

›Use only with adequate renal function (CrCl > 30 mL/min)

09Special Populations/sp46

Pregnancy

›Obstetric hypermagnesemia considerations

›Most common cause in pregnancy: IV magnesium sulfate for preeclampsia or eclampsia prophylaxis

›Therapeutic serum Mg target for eclampsia prophylaxis: 2.0 to 3.5 mmol/l (4 to 7 mEq/L)

›Toxicity thresholds in obstetric patients

›Loss of patellar reflex: Mg approximately 2.0 mmol/l; infusion should be stopped

›Respiratory depression: Mg approximately 2.5 mmol/l

›Cardiac arrest: Mg > 5.0 mmol/l

›Monitoring during IV MgSO4 infusion

›Patellar reflex check every 30 to 60 minutes

›Urine output > 25 mL/hour required to maintain renal excretion

›Respiratory rate > 12 per minute required to continue infusion

›Treatment of toxicity in pregnancy

›Stop MgSO4 infusion immediately

›Calcium gluconate 1 g IV over 5 to 10 minutes (antidote)

›Fetal monitoring; prepare for emergency delivery if needed

›Neonates

›Neonates born to mothers on MgSO4 may have hypermagnesemia, hypotonia, poor feeding, respiratory depression

›Neonatal Mg level at delivery; NICU consultation

›Calcium gluconate 100 to 200 mg/kg IV for neonatal toxicity

Geriatric

›Geriatric-specific considerations

›Elderly patients are highest-risk group due to occult renal impairment plus frequent OTC use

›Often use Mg-containing antacids or laxatives without physician knowledge

›Age-related decline in GFR reduces Mg clearance even without formal CKD diagnosis

›Presentation differences

›Confusion and fall may be the presenting complaint rather than recognized electrolyte symptoms

›Baseline hyporeflexia may obscure early DTR loss

10Background/b51

Epidemiology

›Epidemiological features

›Hypermagnesemia is uncommon in the general population but potentially fatal when severe

›Most cases occur in the setting of renal insufficiency combined with exogenous Mg intake

›Prevalence is highest in CKD patients using Mg-containing OTC products

›Condition is frequently unsuspected; one series found it clinically unsuspected in 6 of 8 patients despite significant sequelae (Clark and Brown, Am J Nephrol 1992)

›Elderly patients using Mg-containing laxatives represent a major at-risk population

›Obstetric patients receiving IV MgSO4 represent a controlled therapeutic risk population requiring mandatory monitoring

›Sporadic cases in patients with normal renal function following massive oral ingestion (Epsom salts, bowel prep) are reported but less common

Pathophysiology

›Magnesium homeostasis

›Approximately 50 to 60% of total body magnesium resides in bone; 1% is extracellular

›Renal excretion is the primary route of magnesium elimination

›Normal kidneys can excrete large Mg loads; hypermagnesemia is rare with intact renal function

›CrCl < 30 mL/min markedly impairs Mg excretion

›GI absorption of Mg is normally 30 to 40%; rises with large oral loads

›Bowel obstruction, ileus, and mucosal injury increase absorption

›Mechanisms of toxicity

›Mg blocks voltage-gated calcium channels at neuromuscular junctions

›Reduces acetylcholine release, causing progressive neuromuscular blockade

›Leads to loss of DTRs, muscle weakness, and respiratory paralysis

›Cardiovascular effects

›Mg causes vasodilation by relaxing vascular smooth muscle (calcium channel blockade)

›Slows conduction through the AV node and His-Purkinje system (calcium channel blockade)

›Results in hypotension, bradycardia, and progressive conduction abnormalities

›Mg inhibits PTH secretion

›Causes secondary hypocalcemia which further worsens cardiac and neuromuscular toxicity

›CNS depression

11Patient Discharge Instructions/pdi22

copy discharge instructions

›Discharge instructions for hypermagnesemia

›What happened: your blood magnesium level was too high, which caused your symptoms (weakness, fatigue, low blood pressure)

›What to avoid

›Do not take any magnesium-containing products without your doctor's approval

›Avoid magnesium-containing antacids: Maalox, Mylanta, Milk of Magnesia

›Avoid magnesium-containing laxatives: magnesium citrate, Milk of Magnesia, Epsom salts

›Avoid magnesium supplements (oral or IV)

›If you need a laxative, use non-magnesium alternatives

›Polyethylene glycol (MiraLAX) is safe

›Docusate sodium (Colace) is safe

›Bisacodyl (Dulcolax) is safe

›Diet: magnesium-rich foods (nuts, seeds, dark chocolate, leafy greens) are rarely dangerous on their own; discuss dietary restriction only if advised by your doctor

›Medications: do not restart any magnesium products unless a doctor specifically prescribes them and is aware of this event

›Kidney disease: if you have kidney disease, you are at higher risk; always check with your doctor before using any OTC antacids, laxatives, or supplements

›Follow-up: repeat blood test within 24 to 48 hours to confirm magnesium level has returned to normal

›Return to emergency department immediately for

›Worsening weakness or inability to lift arms or legs

›Difficulty breathing or shortness of breath

›Lightheadedness, fainting, or chest pain

›Confusion, drowsiness, or difficulty staying awake

›Slow or irregular heartbeat

›Nausea or vomiting preventing oral intake

12References/r18

Guidelines and key sources

›Primary evidence sources

›Clark BA, Brown RS. Unsuspected Morbid Hypermagnesemia in Elderly Patients. American Journal of Nephrology. 1992. PMID: 1489003

›Ayuk J, Gittoes NJ. Contemporary View of the Clinical Relevance of Magnesium Homeostasis. Annals of Clinical Biochemistry. 2014. PMID: 24402002

›Walker P, Parnell S, Dillon RC. Epsom Salt Ingestion Leading to Severe Hypermagnesemia Necessitating Dialysis. Journal of Emergency Medicine. 2020. PMID: 32389435

›Si GF et al. Case Report: Near-Fatal Hypermagnesemia Resulting From the Use of Epsom Salts in a Patient With Normal Renal Function. Frontiers in Medicine. 2024. PMID: 39021819

›William JH, Richards K, Danziger J. Magnesium and Drugs Commonly Used in Chronic Kidney Disease. Advances in Chronic Kidney Disease. 2018. PMID: 29793666

›Weng YM et al. Hypermagnesemia in a Constipated Female. Journal of Emergency Medicine. 2013. PMID: 22244603

›Qureshi T, Melonakos TK. Acute Hypermagnesemia After Laxative Use. Annals of Emergency Medicine. 1996. PMID: 8909278

›Ali A et al. Iatrogenic Acute Hypermagnesemia After TPN Infusion Mimicking Septic Shock Syndrome. Pediatrics. 2003. PMID: 12837909

›Cunningham J, Rodriguez M, Messa P. Magnesium in CKD Stages 3 and 4 and in Dialysis Patients. Clinical Kidney Journal. 2012. PMID: 26069820

›Oliveira B, Cunningham J, Walsh SB. Magnesium Balance in Chronic and End-Stage Kidney Disease. Advances in Chronic Kidney Disease. 2018. PMID: 29793669

›Wolf MT. Inherited and Acquired Disorders of Magnesium Homeostasis. Current Opinion in Pediatrics. 2017. PMID: 27906866

›Quamme GA. Renal Magnesium Handling: New Insights in Understanding Old Problems. Kidney International. 1997. PMID: 9350641

›Sandau KE et al. Update to Practice Standards for Electrocardiographic Monitoring in Hospital Settings. AHA Scientific Statement. Circulation. 2017

›Mosseri M et al. Electrocardiographic Manifestations of Combined Hypercalcemia and Hypermagnesemia. Journal of Electrocardiology. 1990. PMID: 2384729

›Noordam R et al. Effects of Calcium, Magnesium, and Potassium Concentrations on Ventricular Repolarization. JACC. 2019. PMID: 31221261

›Van Hook JW. Endocrine Crises: Hypermagnesemia. Critical Care Clinics. 1991. PMID: 2007216

›Kala J, Abudayyeh A. Magnesium: An Overlooked Electrolyte. Journal of Emergency Medicine. 2017. PMID: 28222929

Learn More: Hypermagnesemia→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.